Comprehensive review of how brain peptides both drive Alzheimer's pathology (amyloid-β, tau) and offer therapeutic promise through neuroprotective analogues, aggregation inhibitors, and brain-targeted peptide conjugates.
Dual role: disease driver and therapeutic targetBrain peptides both cause Alzheimer's (Aβ, tau) and offer treatment solutions through neuroprotective analogues, aggregation inhibitors, and incretin-based approaches
What the researchers found
The review identifies peptides' central role in AD at both pathological and therapeutic levels: Pathogenic peptides (Aβ oligomers, hyperphosphorylated tau fragments) drive synaptic failure, mitochondrial dysfunction, and neuroinflammation. Endogenous neuropeptides provide compensatory neuroprotective, trophic, and homeostatic effects. Therapeutic advances include aggregation inhibitors, receptor-selective neuropeptide analogues, cell-penetrating peptide conjugates, and approaches targeting proteostasis, insulin/incretin signaling, neurotrophic support, and microglial activation. Critical barriers include blood-brain barrier penetration, metabolic stability, off-target effects, and need for biomarker-guided patient stratification.
Why it matters
Alzheimer's disease affects over 55 million people worldwide with limited treatment options. The recognition that peptides are both central to disease pathology and offer unique therapeutic advantages (high specificity, natural brain signaling) positions peptide-based approaches as a promising frontier. The inclusion of incretin/GLP-1 signaling as a therapeutic target also connects to the broader GLP-1 drug revolution.
How the study worked
Comprehensive narrative review integrating evidence on brain peptides in AD pathophysiology, peptide-based therapeutic strategies, and delivery platform advances.
What this study cannot tell us
As a narrative review, this paper provides a broad overview without systematic methodology or quantitative analysis. The field is rapidly evolving, and some discussed therapeutic approaches are at very early stages with limited clinical validation. The challenge of translating peptide therapeutics across the blood-brain barrier remains a fundamental barrier that no review can fully resolve.
How to read the evidence
This is a comprehensive review published in a respected journal, synthesizing evidence across basic science, preclinical, and early clinical studies. The evidence maturity varies widely across the therapeutic strategies discussed — from well-established pathology to speculative therapeutic concepts.
When this study was published
Published in 2026, this is a very current review capturing the latest developments in peptide-based Alzheimer's therapeutics, including recent clinical trial data and emerging delivery technologies.
The bigger picture
This review captures an inflection point in Alzheimer's therapeutics: the first disease-modifying antibodies (lecanemab, donanemab) have been approved, and next-generation peptide-based approaches may offer advantages in specificity, delivery, and combination therapy. The connection between incretin/GLP-1 signaling and neurodegeneration reflects the growing recognition that metabolic peptide pathways influence brain health — a concept now being tested in large clinical trials of semaglutide for Alzheimer's.
Questions still open
- Will GLP-1 receptor agonists prove effective in Alzheimer's clinical trials, validating the incretin-neurodegeneration connection?
- Can brain-penetrating peptide conjugates achieve sufficient concentrations to be therapeutically relevant without off-target effects?
- Could combination peptide therapies targeting both Aβ aggregation and tau pathology simultaneously outperform single-target approaches?
Common questions
How are peptides involved in causing Alzheimer's disease?
Could diabetes drugs like semaglutide help with Alzheimer's?
Read the original research
Brain peptides in Alzheimer's disease - pathophysiology and therapeutic advances.
Cell and tissue research, 403(3)
Citation
Pahal, Sonu; Gupta, Arushi; Kumar, Vivek; Singh, Prashant; Kaushik, Monu; Pahal, Vishvender; Atluri, Geethika; Chaudhary, Amit. (2026). Brain peptides in Alzheimer's disease - pathophysiology and therapeutic advances.. Cell and tissue research, 403(3). https://doi.org/10.1007/s00441-026-04055-8